The Innovation Zone will feature the Startup Stage and Incubator Pavilion over the course of the 3-day international summit

·        Over 400 national and international startups submitted their nominations to showcase their cutting-edge products and services

The Innovation Zone BioAsia 2023 has received an overwhelming response from the startup community, receiving over 400+ applicants from around the world, including some from Singapore, Thailand, the United States, Ireland, and the United Kingdom. The jury panel comprised of senior members from the Government, Incubators, PE/VC firms, and successful entrepreneurs, has shortlisted 75+ promising start-ups from the wide nomination numbers. These startups will be provided space to showcase their invocation at the exhibition. The scrutinization of the applications was based on peculiarity, affordability, and the idea/product’s ability to fulfil the demand. PE and VC firms, investment banks, and angel investors have been invited to the event and budding startups will be given the possible opportunity to network and explore potential collaborations. The participating start-ups will be provided access to all conferences and insightful sessions along with an opportunity to network with the industry leaders of global life sciences. In due course, five startups will be selected by the jury panel to exhibit at the main BioAsia Valedictory session and will also be given exclusive pitch time for each team. They will also be handed over a cash prize along with credits for Amazon cloud. The Startup stage is being organized in partnership with Tech Mahindra and BIRAC, Government of India.

The profile of the startups that will be participating in BioAsia 2023 is highly diverse ranging from medical technology startups manufacturing innovative point-of-care cancer screening kits to futuristic bionic limbs, and from Biotechnology startups formulating small molecule nanoparticles to focusing on the discovery of novel drug candidates. BioAsia is also organizing focused domain-specific round tables for the participating startups.

Mr. Jayesh Ranjan, IAS, Principal Secretary, I&C and IT, Government of Telangana commented, “The sheer number of startup deals and funding is a testimony that Hyderabad has ascended to the country's top 5 start-up hubs. BioAsia has gained global repute through the impact generated by its 19 previous editions. Telangana is the proud home for this year’s “Innovation Zone”, which presents an enormous opportunity for distinctive startups. Hyderabad has already proved its competency as a robust IT hub and we have a lot of technology startups solving issues like simplifying biostatistical analysis, AI-based virtual triaging solutions, and Deep Tech Bioprinters, among more innovative work in the field.”

“In the past twenty years, BioAsia has been built as a platform that has contributed to the growth of not only the Indian but global lifesciences industry. We are confident that startups seeking access to the Indian market, resources, and technology will find a home here. A significant opportunity awaits innovative startups in BioAsia 2023 Innovation Zone,” added Mr. Shakthi Nagappan, Director of Lifesciences, Govt. of Telangana and CEO of BioAsia.

With its 20th edition right around the corner, BioAsia has gained massive prominence across the globe and is expected to attract the participation of more than 3,000 global participants from over 50 countries in the upcoming edition.